Panmure Liberum initiated coverage of PureTech Health with a 'buy' rating and a 200 pence target, citing undervaluation and potential shareholder cash returns. The broker highlighted that PureTech's cash and its stake in Seaport Therapeutics exceed its market value, with $220 million cash as of June 2026 expected to fund operations until at least the end of 2028. A gradual sale of Seaport shares is seen as a likely near-term cash release, supporting management's distribution strategy. Risks include reliance on external funding for drug development, with key upcoming milestones being Seaport's phase IIb trial results and Gallop Oncology's Series A financing in early 2027.
PureTech Health is the story subject, here is Pluang's health sector market snapshot as of Oct 07, 2026 21:21 WIB: Out of 100 US health stocks, 56 rose and 43 fell. Notable movers include WGS at USD 68.80 with a 3.80% drop and 100% buy order activity, TMDX at USD 83.06 up 3.46% with 100% buy orders, and SANA at USD 2.83 up 2.91% with 94% buy orders. Typical hold times range from 19 to 24 days on Pluang.
BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...
Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
